• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬肾同种异体移植的活性增强(作者译)

[Active enhancement of canine kidney allografts (author's transl)].

作者信息

Lie T S, Nakano H, Holst A, Oehr P, Choo S Y

出版信息

Z Immunitatsforsch Exp Klin Immunol. 1976 Apr;151(3):250-3.

PMID:134543
Abstract

In 32 beagles heterotopic renal allotransplantations and bilateral nephrectomies were carried out. Control animals (5 dogs) survived 9.4 +/- 1.6 days. 22 recipients were pretreated with donor-specific semisoluble spleen antigen; 5 recipients pretreated with the antigen alone (780 mg/kg body weight) survived 16.6 +/- 2.3 days. A pretreatment with antigen combined with 5 mg/kg body weight Prednisolone resulted in no significant prolongation of survival time (5 animals), but 5 dogs survived significantly longer after pretreatment with the antigen and 50 mg/kg body weight Prednisolone (27.4 +/- 2,7 days). In 5 recipients after preoperative application of 3 doses Prednisolone alone (50 mg/kg body weight each) no prolongation of survival time could be observed (10.2 +/- 0.7 days). We found no correlation between lymphocytotoxic antibody titre and survival time.

摘要

对32只比格犬进行了异位肾同种异体移植和双侧肾切除术。对照动物(5只狗)存活了9.4±1.6天。22只受体用供体特异性半溶性脾抗原进行预处理;5只仅用抗原(780mg/kg体重)预处理的受体存活了16.6±2.3天。抗原与5mg/kg体重泼尼松龙联合预处理未显著延长存活时间(5只动物),但5只狗在抗原与50mg/kg体重泼尼松龙联合预处理后存活时间显著延长(27.4±2.7天)。5只受体术前单独应用3剂泼尼松龙(每次50mg/kg体重)后未观察到存活时间延长(10.2±0.7天)。我们发现淋巴细胞毒性抗体滴度与存活时间之间没有相关性。

相似文献

1
[Active enhancement of canine kidney allografts (author's transl)].犬肾同种异体移植的活性增强(作者译)
Z Immunitatsforsch Exp Klin Immunol. 1976 Apr;151(3):250-3.
2
Prolongation of allograft and xenograft survival by pretreatment with prednisolone and donor-specific antigen.通过泼尼松龙和供体特异性抗原预处理延长同种异体移植和异种移植的存活时间。
Surg Gynecol Obstet. 1976 Sep;143(3):369-75.
3
Active enhancement of canine liver allografts--effect of pretreatment with prednisolone and donor-specific antigen.犬肝同种异体移植的活性增强——泼尼松龙预处理和供体特异性抗原的作用
Surgery. 1976 Nov;80(5):565-8.
4
Active enhancement of canine liver allografts with polyspecific antigen.用多特异性抗原主动增强犬肝同种异体移植
Surg Gynecol Obstet. 1978 May;146(5):783-8.
5
[Active enhancement of canine liver allografts - simultaneous pretreatment with donor specific semisoluble antigen and prednisolon (author's transl)].犬肝同种异体移植的活性增强——供体特异性半可溶性抗原与泼尼松龙同步预处理(作者译)
Z Immunitatsforsch Exp Klin Immunol. 1974 Nov;148(1):62-72.
6
Active enhancement of dog kidney allografts using ALG and donor platelets.使用抗淋巴细胞球蛋白(ALG)和供体血小板对犬肾同种异体移植物进行主动增强。
Arch Immunol Ther Exp (Warsz). 1978;26(1-6):1013-9.
7
[Active enhancement of canine liver allograft by pretreatment with polyspecific spleen alloantigen (author's transl)].用多特异性脾脏同种异体抗原预处理对犬肝同种异体移植的活性增强作用(作者译)
Langenbecks Arch Chir. 1977 Jul 13;344(1):15-26. doi: 10.1007/BF01259349.
8
[The effect of high-dosage prednisolone administration on antibody formation and graft survival time following allogenic rat kidney transplantation].[高剂量泼尼松龙给药对同种异体大鼠肾移植后抗体形成及移植肾存活时间的影响]
Chir Forum Exp Klin Forsch. 1978(1978):293-8.
9
[Hyperacute rejection of renal xenografts after presensitization of the recipients induced by treatment with donor species-specific spleen antigen (author's transl)].供体物种特异性脾抗原诱导受者致敏后肾异种移植的超急性排斥反应(作者译)
Urol Int. 1979;34(4):291-301. doi: 10.1159/000280273.
10
Active enhancement of rat kidney allografts. Effect of pretreatment with prednisolone and donor-specific antigen.大鼠同种异体肾移植的主动增强。泼尼松龙预处理和供体特异性抗原的作用。
Transplantation. 1976 Feb;21(2):103-9. doi: 10.1097/00007890-197602000-00003.

引用本文的文献

1
[Active enhancement of canine liver allograft by pretreatment with polyspecific spleen alloantigen (author's transl)].用多特异性脾脏同种异体抗原预处理对犬肝同种异体移植的活性增强作用(作者译)
Langenbecks Arch Chir. 1977 Jul 13;344(1):15-26. doi: 10.1007/BF01259349.